FDA Extends Review of FILSPARI sNDA for FSGS, Setting New PDUFA Date for April 2026
Summary
Travere Therapeutics announced the FDA extended the review of its sNDA for FILSPARI in FSGS to April 13, 2026, following a Major Amendment submission for clinical benefit characterization.
Key Events
-
FDA Review Extended for FILSPARI in FSGS
The U.S. Food and Drug Administration (FDA) has extended the review timeline for Travere Therapeutics' supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS).
-
New PDUFA Target Action Date Set
The new Prescription Drug User Fee Act (PDUFA) target action date for the sNDA is now April 13, 2026.
-
Extension Due to Major Amendment
The extension follows the submission of responses requested by the FDA to further characterize the clinical benefit of FILSPARI, which the FDA determined constituted a Major Amendment to the sNDA.
-
No Safety or Manufacturing Concerns Raised
The filing explicitly states that no additional information relating to the safety or manufacturing of FILSPARI has been requested by the FDA.
Analysis
The FDA's decision to extend the review period for FILSPARI's supplemental New Drug Application (sNDA) for focal segmental glomerulosclerosis (FSGS) introduces a delay in potential market entry for this first-in-class therapy. While the extension is due to the FDA requiring more data on clinical benefit rather than safety or manufacturing issues, it signals increased scrutiny and pushes back the PDUFA target action date to April 13, 2026. Investors should monitor the company's communication regarding the additional data provided and any further FDA feedback.
At the time of this filing, TVTX was trading at $28.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $12.91 to $42.13. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.